135 related articles for article (PubMed ID: 16563590)
1. Effects of oral racemic citalopram on neuroendocrine responses.
Hawken ER; Owen JA; Van Vugt D; Delva NJ
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):694-700. PubMed ID: 16563590
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of serotoninergic challenge with oral citalopram.
Mattos P; Franco VA; Noel F; Segenreich D; Gonçalves JC
Braz J Psychiatry; 2006 Sep; 28(3):203-5. PubMed ID: 17063220
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the effects of citalopram and escitalopram on 5-Ht-mediated neuroendocrine responses.
Nadeem HS; Attenburrow MJ; Cowen PJ
Neuropsychopharmacology; 2004 Sep; 29(9):1699-703. PubMed ID: 15127082
[TBL] [Abstract][Full Text] [Related]
4. Low-dose citalopram as a 5-HT neuroendocrine probe.
Attenburrow MJ; Mitter PR; Whale R; Terao T; Cowen PJ
Psychopharmacology (Berl); 2001 May; 155(3):323-6. PubMed ID: 11432696
[TBL] [Abstract][Full Text] [Related]
5. Oral application of citalopram (20 mg) and its usefulness for neuroendocrine challenge tests.
Henning J; Netter P
Int J Neuropsychopharmacol; 2002 Mar; 5(1):67-71. PubMed ID: 14609009
[TBL] [Abstract][Full Text] [Related]
6. L-5-Hydroxytryptophan augments the neuroendocrine response to a SSRI.
Lowe SL; Yeo KP; Teng L; Soon DK; Pan A; Wise SD; Peck RW
Psychoneuroendocrinology; 2006 May; 31(4):473-84. PubMed ID: 16378695
[TBL] [Abstract][Full Text] [Related]
7. Specific effects of escitalopram on neuroendocrine response.
Hawken ER; Owen JA; Hudson RW; Delva NJ
Psychopharmacology (Berl); 2009 Nov; 207(1):27-34. PubMed ID: 19662384
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine effects of citalopram infusion in anorexia nervosa.
Mondelli V; Gianotti L; Picu A; Abbate Daga G; Giordano R; Berardelli R; Pariante CM; Fassino S; Ghigo E; Arvat E
Psychoneuroendocrinology; 2006 Nov; 31(10):1139-48. PubMed ID: 17045409
[TBL] [Abstract][Full Text] [Related]
9. Effect of sleep deprivation on neuroendocrine response to a serotonergic probe in healthy male subjects.
Seifritz E; Müller MJ; Annen O; Nil R; Hatzinger M; Hemmeter U; Moore P; Holsboer-Trachsler E
J Psychiatr Res; 1997; 31(5):543-54. PubMed ID: 9368196
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine effects of citalopram, a selective serotonin re-uptake inhibitor, during lifespan in humans.
Berardelli R; Margarito E; Ghiggia F; Picu A; Balbo M; Bonelli L; Giordano R; Karamouzis I; Bo M; Ghigo E; Arvat E
J Endocrinol Invest; 2010 Oct; 33(9):657-62. PubMed ID: 20414043
[TBL] [Abstract][Full Text] [Related]
11. The effects of an acute serotonergic challenge on brain-gut responses in irritable bowel syndrome patients and controls.
Kilkens TO; Honig A; Fekkes D; Brummer RJ
Aliment Pharmacol Ther; 2005 Nov; 22(9):865-74. PubMed ID: 16225497
[TBL] [Abstract][Full Text] [Related]
12. Citalopram challenge in social anxiety disorder.
Shlik J; Maron E; Tru I; Aluoja A; Vasar V
Int J Neuropsychopharmacol; 2004 Jun; 7(2):177-82. PubMed ID: 14741063
[TBL] [Abstract][Full Text] [Related]
13. S-Citalopram in neuroendocrine challenge-tests: serotonergic responsivity in healthy male and female human participants.
Kuepper Y; Bausch S; Iffland J; Reuter M; Hennig J
Psychoneuroendocrinology; 2006 Nov; 31(10):1200-7. PubMed ID: 17123742
[TBL] [Abstract][Full Text] [Related]
14. In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram.
Klein N; Sacher J; Geiss-Granadia T; Attarbaschi T; Mossaheb N; Lanzenberger R; Pötzi C; Holik A; Spindelegger C; Asenbaum S; Dudczak R; Tauscher J; Kasper S
Psychopharmacology (Berl); 2006 Oct; 188(3):263-72. PubMed ID: 16955282
[TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influences.
Lotrich FE; Bies R; Muldoon MF; Manuck SB; Smith GS; Pollock BG
Psychopharmacology (Berl); 2005 Mar; 178(2-3):268-75. PubMed ID: 15365685
[TBL] [Abstract][Full Text] [Related]
16. Administration of citalopram before ECT: seizure duration and hormone responses.
Papakostas YG; Markianos M; Zervas IM; Theodoropoulou M; Vaidakis N; Daras M
J ECT; 2000 Dec; 16(4):356-60. PubMed ID: 11314873
[TBL] [Abstract][Full Text] [Related]
17. Paroxetine as a 5-HT neuroendocrine probe.
Kojima H; Terao T; Iwakawa M; Soya A; Inoue N; Shiraishi Y; Son Y; Soeda S; Ueda N; Yoshimura R; Nakamura J
Psychopharmacology (Berl); 2003 Apr; 167(1):97-102. PubMed ID: 12601506
[TBL] [Abstract][Full Text] [Related]
18. Hormone responses to citalopram in abstinent alcohol dependent subjects.
Gotjen D; Szabo Z; Lee S; Wand G
Alcohol Clin Exp Res; 2002 Nov; 26(11):1625-31. PubMed ID: 12436050
[TBL] [Abstract][Full Text] [Related]
19. Dissociable hormonal, cognitive and mood responses to neuroendocrine challenge: evidence for receptor-specific serotonergic dysregulation in depressed mood.
Riedel WJ; Klaassen T; Griez E; Honig A; Menheere PP; van Praag HM
Neuropsychopharmacology; 2002 Mar; 26(3):358-67. PubMed ID: 11850150
[TBL] [Abstract][Full Text] [Related]
20. Escitalopram prolonged fear induced by simulated public speaking and released hypothalamic-pituitary-adrenal axis activation.
Garcia-Leal C; Del-Ben CM; Leal FM; Graeff FG; Guimarães FS
J Psychopharmacol; 2010 May; 24(5):683-94. PubMed ID: 19251828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
